Other important prognostic biomarkers, like the IDH1 mutation and the related G‐CIMP phenotype, are diagnostically relevant since tumors with IDH1 mutations are now formally excluded from the group of glioblastoma but are named astrocytomas even in the presence of microvascular proliferation or necrosis. This evidence concerns the gene IDH1 and glioblastoma.